Beneficial Ownership Report · SCHEDULE 13D/A
SenesTech, Inc.
SNESNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13D/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- SenesTech, Inc.
- Company CIK
- 0001680378
- Street
- 13430 NORTH DYSART ROAD
- Street (continued)
- SUITE 105
- City
- SURPRISE
- State / country code
- AZ
- Postal code
- 85379
Statement details
- Amendment number
- 3
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 10/28/2026
- Previously filed indication
- true
Authorized notification person 1
- Name
- Glenbrook Capital Management
- Phone
- 650-441-9525
- Street
- 2207, Suite B
- Street (continued)
- Bellanca St.
- City
- Minden
- State / country code
- NV
- Postal code
- 89423
Authorized notification person 2
- Name
- Ele Klein & Danny Goldstein
- Phone
- 212-756-2446
- Street
- McDermott Will & Schulte LLP
- Street (continued)
- 919 Third Avenue
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Reporting person 1
- Name
- GLENBROOK CAPITAL MANAGEMENT
- Reporting person CIK
- 0001273782
- No reporting person CIK indication
- N
- Citizenship / organization
- NV
- Reporting person type
- CO
- Source of funds code
- AF
- Legal proceedings indication
- N
- Aggregate amount owned
- 2,196,973.00
- Percent of class
- 40.51
- Sole voting power
- 0.00
- Shared voting power
- 2,196,973.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,196,973.00
- Aggregate excludes certain shares
- N
- Comments
- Based on 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026.
Item 1
Issuer
SenesTech, Inc.
Security title
Common Stock, par value $0.001 per share
Principal address
Comment
This Amendment No. 3 ("Amendment No. 3") amends the statement on Schedule 13D filed with the SEC on July 23, 2026, as amended by Amendment No. 1 filed with the SEC on October 19, 2026 and Amendment No. 2 filed with the SEC on October 22, 2026 (as amended, the "Schedule 13D") with respect to the Common Stock of the Issuer. This Amendment No. 3 amends Item 3, Item 4, and 5(a)-(c), as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D.
Item 3
Source of funds
Item 3 is hereby amended and restated as follows: Funds for the purchase of the securities reported herein were derived from the general working capital of the Glenbrook Funds and Accounts. A total of approximately $4.43 million (excluding brokerage commissions) was paid to acquire shares of Common Stock during the period in which the Reporting Person has been subject to reporting obligations under Section 13(d) or 13(g) of the Act with respect to the Common Stock. Such amount does not include the price of shares of Common Stock acquired and/or sold by the Reporting Person prior to such period.
Item 4
Purpose of transaction
Item 4 is hereby amended and supplemented by adding the following: In April 2026, the Reporting Person commissioned, at its expense, a strategic study of the rodent control market by Sandstrom Partners, Inc. ("Sandstrom"), the results of which were presented to the Board. On October 28, 2026, the Issuer announced that it had engaged Sandstrom as a strategic advisor on marketing and branding. The Reporting Person holds a minority ownership interest in Sandstrom.
Item 5
Number of shares
Item 5(b) is hereby amended and restated as follows: See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
Transactions
Item 5(c) is hereby amended and restated as follows: All transactions in the shares of Common Stock effected by the Reporting Person since the filing of Amendment No. 2, which were all in the open market, are set forth in Schedule A hereto, and are incorporated herein by reference.
Percentage of class
Item 5(a) is hereby amended and restated as follows: See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of shares of Common Stock beneficially owned by the Reporting Person. The aggregate percentage of shares of Common Stock reported to be beneficially owned by the Reporting Person is based upon 5,423,542 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 6, 2026.
Item 7
Filed exhibits
EX 99.1 TRANSACTIONS IN SECURITIES OF THE ISSUER
Signature 1
- Reporting person
- GLENBROOK CAPITAL MANAGEMENT
- Signed
- /s/ Robert W. Lishman
- Title
- Robert W. Lishman, Director
- Date
- 10/30/2026
Filed exhibits
- SCHEDULE A ↗e8032_ex99.htm
Company context
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company’s groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech’s mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.
Current securities
Historical securities (1)
Recent company filings
- Results of Operations and Financial ConditionNov 10, 2026
- 4 filingOct 30, 2026
- 4 filingOct 22, 2026
- SCHEDULE 13D/A - filed by GLENBROOK CAPITAL MANAGEMENT regarding SenesTech, Inc.Oct 22, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD DisclosureOct 22, 2026